Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: Report of 102 cases and review of literature

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Matsumoto, Kazuhiro ^a   Tanaka, Nobuyuki ^b   Hayakawa, Nozomi ^a   Ezaki, Taisuke ^a   Suzuki, Kenjiro ^a   Maeda, Takahiro ^a   Ninomiya, Akiharu ^a   Nakamura, So ^a  

^a SAISEIKAI CENTRAL HOSPITAL   (Japan)

^b Saitama Municipal Hospital   (Japan)

Author keywords

CRPC; EMP; Estramustine phosphate sodium hydrate; PSA

Indexed keywords

ANTIANDROGEN; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; ETHINYLESTRADIOL; HORMONE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; UFT; ALKYLATING AGENT; ESTRAMUSTINE;

ADULT; AGED; ANTIANDROGEN THERAPY; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GYNECOMASTIA; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ARTICLE; BLOOD; CASTRATION; METHODOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CASTRATION; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84891870018     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0717-2     Document Type: Review

References (23)

1. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235-46.
2. Labrie F. Hormonal therapy of prostate cancer. Prog Brain Res. 2010;182:321-41.
3. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int. 2005;96:791-5. (Pubitemid 41391382)
4. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol. 2004;171:679-83. (Pubitemid 38090455)
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20. (Pubitemid 39315318)
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12. (Pubitemid 39315317)
7. Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S, et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol. 2008;38:365-72. (Pubitemid 351753569)
8. Miura N, Numata K, Kusuhara Y, Shirato A, Hashine K, Sumiyoshi Y. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. Jpn J Clin Oncol. 2010;40:1092-8.
9. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol. 1997;15:13-9. (Pubitemid 27091622)
10. Maier U, Hienert G, Simak R. Estramustine phosphate in secondary hormone-resistant carcinoma of the prostate. Eur Urol. 1990;17:216-8. (Pubitemid 20142961)
11. Elomaa I, Kellokumpu-Lehtinen P, Rannikko S, Alfthan O. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments. Eur Urol. 1991;19:12-5.
12. Johansson JE, Andersson SO, Holmberg L. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. Br J Urol. 1991;68:67-73.
13. Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865). J Urol. 1993;150:1840-4. (Pubitemid 24350813)
14. Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol. 1997;157:929-34. (Pubitemid 27066281)
15. Albrecht W, Van Poppel H, Horenblas S, Mickisch G, Horwich A, Serretta V, et al. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer. 2004;90:100-5. (Pubitemid 38174946)
16. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, et al. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int. 2005;75:43-9. (Pubitemid 41022593)
17. Naiki T, Okamura T, Kawai N, Sakagami H, Yamada Y, Fujita K, et al. Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients. Asian Pac J Cancer Prev. 2009;10:71-4.
18. Serretta V, Altieri V, Morgia G, Siragusa A, De Grande G, Napoli M, et al. Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. Urol Int. 2009;83:452-7.
19. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother. 2010;59:1001-9.
20. Minato A, Fujimoto N, Kubo T, Harada S, Akasaka S, Matsumoto T. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer. Med Oncol. 2012;29:2895-900.
21. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-59.
22. Maffezzini M, Bossi A, Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol. 2007;51:605-13. (Pubitemid 46097288)
23. Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med. 2000;19:113-32. (Pubitemid 30051256)